Summary by Moomoo AI
CSPC Pharma announced unaudited interim results ending on June 30, 2024, achieving revenue of RMB162.84 billion, a year-on-year increase of 1.3%. The basic earnings per share attributable to shareholders were RMB3.217 billion, an increase of 1.7% year-on-year. The earnings per share attributable to shareholders were RMB3.02 billion, an increase of 1.8% year-on-year. The company announced a mid-year dividend of HKD 0.16 per share, an increase of 14.3% from the same period last year, and will be distributed on November 20, 2024. In addition, the company has completed HKD 0.387 billion of share buybacks and plans to buy back up to HKD 1 billion of shares. CSPC Pharma is a pharmaceutical company that integrates research and development, production, and sales. There are currently about 130 innovative drug projects under development, with nearly 50 new products/adaptation declarations expected to be listed in the next five years.
